Spectrin beta chain non-erythrocytic 1 (SPTBN1)

Spectrin beta chain non-erythrocytic 1 (SPTBN1), also known as Beta-II spectrin, is a fundamental cytoskeletal and scaffolding protein that links the plasma membrane to the actin cytoskeleton. It plays a pivotal role in maintaining cell shape, polarity, and the organization of intracellular organelles. Beyond its structural contributions, SPTBN1 is a critical regulator of signal transduction, specifically acting as a key adapter in the TGF-beta/Smad pathway to control cell proliferation, apoptosis, and differentiation across various tissues. In human pathology, dysregulation of SPTBN1 is associated with a spectrum of diseases including hepatocellular carcinoma, where it often acts as a tumor suppressor, and nonalcoholic steatohepatitis (NASH), where it promotes lipogenesis. Furthermore, recent genomic studies have identified de novo mutations in SPTBN1 as the primary cause of an autosomal dominant neurodevelopmental syndrome characterized by intellectual disability and autism. While no FDA-approved drugs currently target SPTBN1 directly, it is an area of active investigation for siRNA-based therapies and precision oncology, particularly for its role in metabolic liver disease and cancer progression.

Other names

Beta-II spectrinELFEmbryonic liver beta-fodrinFodrin beta chainSPTB2betaSpIIDDISBA

Experimental siRNA-mediated therapy works by targeting SPTBN1 mRNA for degradation, thereby reducing protein levels and inhibiting its interaction with SREBP1 to suppress lipogenesis and fibrosis in liver disease models. It also modulates the TGF-beta/SMAD signaling pathway to influence tumor growth and differentiation.